Table I. Baseline patient characteristics.
| Patients N (%) |
Age at implant, y Mean (range) |
Ethnicity N (%) |
CNS* abnormality N (%) |
Previous GnRHa treatment N (%) |
Pubertal staging |
|---|---|---|---|---|---|
| All | 7.2 ± 2.5 (2.2-10.8) | White-24 (73) | 4 (12) | 13 (39) | |
| 33 | Black-5 (15) | ||||
| Biracial-2 (6) | |||||
| Hispanic-1 (3) | |||||
| East Indian-1 (3) | |||||
| Girls | 7.13 ± 3.2 (2.2-10.5) | White-20 (77) | 3 (12) | 12 (46) | Breast Tanner stage, % |
| 26 (79) | Black-5 (19) | II-4, III-73, IV-23 | |||
| Hispanic-1 (4) | Menarche, N (%) | ||||
| 2 (8) | |||||
| Boys | 7.5 ± 3.2 (2.5-10.8) | White-4 (57) | 1 (14) | 1 (14) | Testicular volume, mL |
| 7 (21) | Biracial-2 (29) | 4, 4-5, 8-10, 10,10-12, 12, 12-15 | |||
| East Indian-1 (14) |
CNS, central nervous system.
*
Hypothalamic hamartoma (n = 2), neurofibromatosis-1 with optic glioma (n = 1), and hypothalamic glioma (n = 1).